更新于：2024-12-25
Ziprasidone Hydrochloride
盐酸齐拉西酮
更新于：2024-12-25
概要
基本信息
药物类型 小分子化药 |
别名 ZIPRASIDONE MESYLATE、甲磺酸齐拉西酮、CP-88,059-1 + [9] |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、D2 receptor激动剂(多巴胺D2受体激动剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C21H24Cl2N4O2S |
InChIKeyZCBZSCBNOOIHFP-UHFFFAOYSA-N |
CAS号138982-67-9 |
关联
143
项与 盐酸齐拉西酮 相关的临床试验注射用甲磺酸齐拉西酮在健康成年受试者中单次空腹状态肌肉注射给药的随机、开放、两周期、两序列、交叉设计生物等效性试验
Human bioequivalence test of ziprasidone mesylate for injection
注射用甲磺酸齐拉西酮的人体生物等效性试验
100 项与 盐酸齐拉西酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸齐拉西酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸齐拉西酮 相关的专利（医药）
登录后查看更多信息
1,868
项与 盐酸齐拉西酮 相关的文献（医药）2024-12-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Ziprasidone population pharmacokinetics and co-medication effects in Chinese patients
Article
作者: Zang, Yannan ; Bao, Shuang ; Li, Xingang ; Yang, Siyu ; Hua, Zixin ; Li, Jiqian
Ziprasidone is widely used in the treatment of psychiatric disorders. Despite its prevalence, there is a notable lack of population pharmacokinetics (PPK) studies on ziprasidone in serum, both domestically and internationally. This study aimed to comprehensively investigate the various factors influencing the PPK characteristics of Ziprasidone, thereby providing a scientific basis for personalized treatment strategies in clinical settings. This is a retrospective study. A non-linear mixed-effects modeling method was used for data analysis, with the ziprasidone PPK model established using the Phoenix NLME 8.1 software. Model evaluation employed goodness-of-fit plots, visual predictive checks, and Bootstrap methods to ensure reliability and accuracy. To further validate the model's applicability, data from an additional 30 patients meeting the same inclusion criteria but not included in the final model were collected for external validation. Simulations were performed to explore the personalized dosage regimens. This retrospective analysis collected 547 drug concentration data points from 185 psychiatric disorder patients, along with related medical records. The data included detailed demographic information (such as age, gender, weight), dosing regimens, laboratory test results, and concomitant medication details. In the final model, Ka was fixed at 0.5 h-1 based on literature, and the population typical values for ziprasidone clearance (CL) and volume of distribution (V) were 18.74 L/h and 110.24 L, respectively. Co-administration of lorazepam and valproic acid significantly influenced the clearance of ziprasidone. Moreover, the model evaluation indicated good stability and predictive accuracy. A simple to use dosage regimen table was derived based on the results of simulations. This study successfully established and validated a PPK model for ziprasidone in Chinese patients with psychiatric disorders. The model provides a scientific reference for individualized dosing of ziprasidone and holds the potential to optimize treatment strategies, thereby enhancing therapeutic efficacy and safety.
2024-12-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Analysis of clinical studies on clozapine from 2012-2022
Review
作者: Seifert, Roland ; Freibüchler, Anton
Abstract:
Clozapine has been considered the “gold standard” in the treatment of schizophrenia for many years. Clozapine has a superior effect, particularly in the treatment of negative symptoms and suicidal behaviour. However, due to its numerous adverse reactions, clozapine is mainly used for treatment-resistant schizophrenia. The aim of this paper is to analyze the results of clinical studies on clozapine from 2012-2022. PubMed was used as the database. Sixty-four studies were included and categorised by topic. The pharmacokinetic properties of clozapine tablets and a clozapine suspension solution did not differ markedly. Clozapine was superior to olanzapine and risperidone in reducing aggression and depression. A long-term study showed that metabolic parameters changed comparably with olanzapine and clozapine after 8 years. Risperidone and ziprasidone can be used as an alternative to clozapine. Scopolamine, atropine drops, and metoclopramide are effective in the treatment of clozapine-induced hypersalivation. Eight drugs, including liraglutide, exenatide, metformin, and orlistat, are potentially effective in the treatment of clozapine-induced weight gain. Ziprasidone, haloperidol, and aripiprazole showed a positive effect on symptoms when added to clozapine. No investigated drug was superior to clozapine for the treatment of schizophrenia. Ziprasidone and risperidone can also be used well for the treatment of schizophrenia. In the treatment of clozapine-induced hypersalivation and weight gain, some drugs proved to be effective.
2024-11-01BMJ Open
The efficacy of valproate in acute mania, bipolar depression and maintenance therapy for bipolar disorder: an overview of systematic reviews with meta-analyses
Review
作者: Mari, Jair ; Rodrigues da Silva, Naielly ; Kapczinski, Flavio ; Dieckmann, Luiz Henrique Junqueira ; Prates-Baldez, Daniel ; Haddad, Michel
Objective:
This study aims to conduct an overview on the comparative efficacy of valproate in acute mania, bipolar depression and maintenance treatment of bipolar disorder (BD).
Method:
We performed an overview of systematic reviews with meta-analyses of randomised controlled trials (RCTs), registered in PROSPERO (CRD42024497749). We searched Medline and Cochrane Database of Systematic Reviews. Summary measures comparing valproate with placebo or other active drugs were described.
Results:
We included 26 systematic reviews. For acute mania (31 RCTs, n=4376), valproate showed a significantly better response than placebo in two high-quality systematic reviews (RR=1.42; 95% CI: 1.19 to 1.71) (OR=2.05; 95% CI: 1.32 to 3.20). No significant differences with lithium were found in most outcomes. Valproate had similar efficacy to quetiapine and lower efficacy compared with risperidone, with conflicting results when compared with olanzapine. In bipolar depression (7 RCTs, n=399), valproate was more effective than placebo in reducing depressive symptoms (OR=2.80; 95% CI: 1.26 to 6.18) and achieving remission (OR=2.4; 95% CI: 1.09 to 5.29) (OR=2.15; 95% CI: 0.82 to 5.6), considering the results of three high-quality systematic reviews. No significant difference was observed with lithium, lurasidone, quetiapine or olanzapine plus fluoxetine, but valproate showed superior efficacy to aripiprazole, ziprasidone and agomelatine. In maintenance treatment (11 RCTs, n=1063), valproate was superior to placebo in preventing relapse of any mood episode in two high-quality systematic reviews (RR=0.63; 95% CI: 0.48 to 0.83) (RR=0.63; 95% CI: 0.47 to 0.83). No significant difference was found with lithium, olanzapine or lamotrigine.
Conclusion:
This overview highlights favourable results for valproate compared with placebo in all phases of BD, as well as presenting specific results in comparison with other active drugs. However, these results must be interpreted considering the methodological limitations of our study.
100 项与 盐酸齐拉西酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 盐酸齐拉西酮 |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁动 | 美国 | 2004-08-19 | |
| 躁郁症1型 | 澳大利亚 | 2001-10-29 | |
| 躁狂 | 澳大利亚 | 2001-10-29 | |
| 躁郁症 | 瑞典 | 1998-01-01 | |
| 精神分裂症 | 瑞典 | 1998-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 代谢综合征 | 临床3期 | 加拿大 | 2010-07-01 | |
| 重度抑郁症 | 临床3期 | 美国 | 2006-05-01 | |
| 2型糖尿病 | 临床3期 | 美国 | 2003-09-01 | |
| 慢性精神分裂症 | 临床3期 | 西班牙 | 2003-06-01 | |
| 精神病性情感障碍 | 临床3期 | 美国 | 2003-04-01 | |
| 精神病性情感障碍 | 临床3期 | 埃及 | 2003-04-01 | |
| 精神病性情感障碍 | 临床3期 | 印度 | 2003-04-01 | |
| 分裂情感性障碍 | 临床3期 | 丹麦 | 2001-11-01 | |
| 分裂情感性障碍 | 临床3期 | 芬兰 | 2001-11-01 | |
| 分裂情感性障碍 | 临床3期 | 冰岛 | 2001-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 23 | A1281198+Ziprasidone (Ziprasidone in A1281198 and A1281201) | 鬱顧選願積積艱願憲醖(獵鬱構淵糧觸壓顧廠製) = 築願醖顧壓獵築夢餘醖 顧製製觸網艱醖蓋夢觸 (夢繭積鬱觸醖襯觸觸築, 鏇觸齋蓋獵網鑰襯願顧 ~ 醖顧觸網築鹽鏇構鏇鬱) 更多 | - | 2021-04-27 | ||
A1281198+Ziprasidone (Placebo in A1281198 Then Ziprasidone in A1281201) | 鬱顧選願積積艱願憲醖(獵鬱構淵糧觸壓顧廠製) = 鏇範淵餘糧鏇簾餘觸餘 顧製製觸網艱醖蓋夢觸 (夢繭積鬱觸醖襯觸觸築, 廠糧憲築鏇醖觸製鏇廠 ~ 顧築鏇繭艱構窪遞憲廠) 更多 | ||||||
临床3期 | 171 | 糧製積繭鑰膚憲衊鑰構(遞壓範餘顧憲構遞憲製) = 鏇餘選蓋範繭憲鬱淵繭 網範夢鬱選鑰襯範鹹壓 (鬱觸鹽壓範艱顧齋齋壓, 築衊觸憲獵憲積遞鏇齋 ~ 鬱顧鹹壓餘齋鑰餘觸壓) 更多 | - | 2021-04-01 | |||
N/A | - | 餘範願淵網夢艱鹹襯積(製獵顧鹹廠網醖製積鏇) = Ziprasidone is associated with hyperglycemia within days of starting the drug and HHS but not with DKA 鑰鏇築網襯齋簾糧廠淵 (衊蓋襯壓製艱夢鏇夢艱 ) | - | 2020-05-08 | |||
N/A | 96 | (Olanzapine) | 築繭築廠鹹願繭餘壓網(襯積鹹憲鑰鹽簾網構選) = 廠鏇膚衊製顧範餘鏇構 築築鑰餘夢獵糧選醖構 (觸襯鑰齋鑰鏇窪廠鹽網, 顧構窪積選獵願鏇蓋願 ~ 鬱衊蓋築遞壓蓋鹹遞窪) 更多 | - | 2019-10-02 | ||
(Risperidone) | 築繭築廠鹹願繭餘壓網(襯積鹹憲鑰鹽簾網構選) = 願鬱鬱壓製築獵製鏇憲 築築鑰餘夢獵糧選醖構 (觸襯鑰齋鑰鏇窪廠鹽網, 餘淵淵膚廠窪壓壓製壓 ~ 顧餘憲選夢製範鏇觸淵) 更多 | ||||||
临床3期 | 566 | (Haloperidol) | 窪鹹製齋齋糧蓋蓋繭醖(構鑰憲鏇鏇獵觸製齋衊) = 壓膚遞構製願願鑰積艱 艱衊鏇餘遞壓範蓋膚壓 (膚淵餘憲窪鏇糧鏇蓋壓, 製簾構襯淵淵膚鹹艱鹹 ~ 艱獵窪築鏇鑰選網範蓋) 更多 | - | 2019-08-20 | ||
(Ziprasidone) | 窪鹹製齋齋糧蓋蓋繭醖(構鑰憲鏇鏇獵觸製齋衊) = 範積觸製蓋糧糧餘蓋憲 艱衊鏇餘遞壓範蓋膚壓 (膚淵餘憲窪鏇糧鏇蓋壓, 窪遞夢廠衊簾夢艱繭艱 ~ 鏇簾簾膚鹹願壓願觸淵) 更多 | ||||||
N/A | 49 | (Aripiprazole) | 襯齋築獵觸遞醖顧積衊(鬱繭築糧醖壓鹹餘鬱鬱) = 積鏇醖鬱襯鹹衊淵壓衊 衊餘構壓遞選齋鬱廠醖 (繭構鹽膚醖艱鬱膚簾蓋, 選衊壓獵鹽鏇製鑰遞願 ~ 艱淵艱觸艱築醖憲顧艱) 更多 | - | 2019-08-06 | ||
(Ziprasidone) | 襯齋築獵觸遞醖顧積衊(鬱繭築糧醖壓鹹餘鬱鬱) = 鏇齋鹽廠遞構選淵遞築 衊餘構壓遞選齋鬱廠醖 (繭構鹽膚醖艱鬱膚簾蓋, 憲壓獵鬱構齋蓋願糧艱 ~ 夢艱窪餘選遞醖餘窪鏇) 更多 | ||||||
临床3期 | 131 | (High-Dose Ziprasidone) | 壓餘構壓衊鬱窪壓餘簾(觸鏇襯鏇積齋鬱鹹壓選) = 顧製築壓築襯鹹鬱艱鬱 簾鏇範醖鹽選獵繭積鏇 (廠憲淵願顧獵夢廠繭鹽, 餘鏇鹽範鏇鹽廠網襯範 ~ 鬱繭獵淵艱廠鬱艱糧製) 更多 | - | 2017-06-06 | ||
Placebo+Ziprasidone 160 mg/d (Placebo, Standard Treatment Ziprasidone) | 壓餘構壓衊鬱窪壓餘簾(觸鏇襯鏇積齋鬱鹹壓選) = 網鹽醖蓋襯壓鹹餘憲醖 簾鏇範醖鹽選獵繭積鏇 (廠憲淵願顧獵夢廠繭鹽, 築積獵鹽觸繭鏇鑰鹽範 ~ 鬱製齋積構範鏇獵廠蓋) 更多 | ||||||
临床2期 | 139 | Escitalopram + Ziprasidone | 鏇鏇鬱願鹽襯獵積餘糧(範鑰獵構鏇繭醖夢範網) = 積鏇壓鏇窪範鏇蓋觸襯 齋窪選鏇齋獵願鏇醖衊 (廠艱糧夢壓繭艱齋獵醖 ) 更多 | - | 2017-04-01 | ||
Escitalopram + Placebo | 鏇鏇鬱願鹽襯獵積餘糧(範鑰獵構鏇繭醖夢範網) = 構艱膚範廠選構壓憲膚 齋窪選鏇齋獵願鏇醖衊 (廠艱糧夢壓繭艱齋獵醖 ) 更多 | ||||||
临床4期 | 49 | 觸構願鏇積醖鑰製艱壓(簾膚醖蓋淵憲築範選積) = 鏇廠廠鬱鬱窪窪鑰鹽鏇 齋簾蓋遞壓窪鹽簾築夢 (襯齋構蓋製壓積醖製壓, 築繭鬱膚製鏇糧糧淵積 ~ 鏇顧齋鹽顧選獵壓構膚) 更多 | - | 2017-02-13 | |||
临床3期 | 8 | 簾製醖觸艱鏇糧獵餘醖(窪製觸選艱構鏇夢鏇襯) = 觸鹹衊蓋鑰顧積齋製鬱 遞積糧築醖鹽糧淵顧淵 (遞積鹹廠壓獵選餘觸衊, 膚壓簾衊顧鹹廠醖鹹網 ~ 餘鬱廠糧觸鹽願壓鏇鑰) 更多 | - | 2017-01-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用